Lantern Pharma (NASDAQ: LTRN) will present the growth plan for its wholly owned subsidiary Open-Medicine AI (OMAI) during a live webinar today at 12:30 p.m. Eastern. CEO Panna Sharma will lead the 45-minute session, covering the market opportunity for OMAI, customer feedback, platform capabilities, development roadmap, economics, benchmarks, potential partnerships, and the subsidiary’s contribution to shareholder value.
OMAI is developing a multi-agentic AI platform for drug development. Its core capabilities and initial platform were developed within Lantern’s clinical programs and areas of focus. Launched as withZeta.ai in April 2026 with an initial focus on rare cancers, the platform is now expanding into additional diseases, therapy types, and stages of drug development. The webinar will include a live demonstration of the platform followed by a question-and-answer session.
The announcement matters because it signals Lantern’s push to commercialize AI-driven drug development beyond its own pipeline. By spinning out OMAI as a wholly owned subsidiary, Lantern aims to capture a broader market opportunity in AI-enabled drug discovery, potentially opening new revenue streams and partnerships. The live demo and Q&A offer investors and potential customers a direct look at the platform’s capabilities and roadmap, which could influence the company’s valuation and strategic direction.
Lantern Pharma is a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify the patients most likely to benefit from Lantern’s therapies and to guide biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.
For more details on the webinar and OMAI, see the full press release at https://ibn.fm/SpEDF. The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN. Additional information on Lantern Pharma can be found at Lantern Pharma (NASDAQ: LTRN).
AINewsWire, a specialized communications platform focused on artificial intelligence, is one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The network provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit www.AINewsWire.com.
